ArticleJournal of diabetes investigation2026
Polygenic risk score refines cardiovascular disease risk in individuals with type 2 diabetes at borderline or intermediate risk.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic basis of Asian diabetes.Journal of diabetes investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To evaluate whether a coronary artery disease (CAD) polygenic risk score (PRS) can improve atherosclerotic cardiovascular disease (ASCVD) risk stratification in individuals with type 2 diabetes (T2D), particularly those at borderline or intermediate 10-year risk. In the UK Biobank (n = 340,299), we integrated CAD PRS into the Pooled Cohort Equations (PCE) to evaluate whether it improved the prediction of incident ASCVD in individuals with T2D at borderline and intermediate 10-year risk. CAD PRS was associated with ASCVD in T2D (1.18-fold). Among those at borderline and intermediate risk, PRS was strongly predictive (1.47-fold and 1.11-fold), and individuals in the top 10% had 1.86-fold and 1.32-fold higher risk. Integration of PRS into PCE modestly improved AUROC (0.050, P = 0.024) and significantly improved net reclassification (0.343, P = 2.62 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.